Who owns Fulgent Genetics, Inc. (FLGT)? Elite investor 13F holders

3 tracked elite investors reported holding Fulgent Genetics, Inc as of 2026-06-30, including D.E. Shaw, Tudor Investment, Ancora Advisors / Ancora Holdings. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

3 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Health Care Equipment & Services

Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast…

Reported holders and securities, including exits (up to 20)

Reported holders and securities, including exits (up to 20)
InvestorSecurityInstrumentReport periodFiledValueQuantityUnitsChangeSource
D.E. ShawFULGENT GENETICS INCSHARE2026-06-302026-08-14 00:00:005991963.00 USD292006.000000SharesreduceOriginal filing
Tudor InvestmentFULGENT GENETICS INCSHARE2026-06-302026-08-14 00:00:001677038.00 USD81727.000000SharesaddOriginal filing
Renaissance Technologies LLCFULGENT GENETICS INCSHARE2026-06-302026-08-13 00:00:000.00 USD0.000000SharesexitedOriginal filing
Ancora Advisors / Ancora HoldingsFULGENT GENETICS INCSHARE2026-06-302026-08-14 00:00:0010260.00 USD500.000000SharesholdOriginal filing

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

How to read the data · Disclaimer

Read as Markdown